SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

February 11, 2013 10:15 ET

Implant Sciences' QS-B220 to Be Featured at Security Conference in Russia

WILMINGTON, MA--(Marketwire - Feb 11, 2013) -  Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its new Sales Director for Russia, Natalya Hall will be presenting the Company's TSA-approved Quantum Sniffer™ QS-B220 desktop explosives and drugs trace detector at the Security and Safety Technologies conference in Moscow on February 12th through 15th, 2013. Implant Sciences' distributor for Russia, Strateb LLC will feature the QS-B220 at booth #C23.

TB Forum's 18th annual Security and Safety Technologies conference presents the latest security technologies, solutions and services for major Russian end-users in applications including law-enforcement, IT, communications, transportation, manufacturing, trade, infrastructure sites, and construction.

The Russian government announced in February of 2011 that it plans to spend $1.6 billion on transportation security for the three year period following the announcement.

"With a strong distributor and our new Sales Director for Russia in place, we are well positioned to expand sales in the Russian market and look forward growing our market presence and installations in the region," stated Implant Sciences' President and CEO, Glenn D. Bolduc.

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact